Results 11 to 20 of about 5,782 (258)
The landscape of bispecific T cell engager in cancer treatment [PDF]
Biomarker Research, 2021 T cell-based immunotherapies have revolutionized treatment paradigms in various cancers, however, limited response rates secondary to lack of significant T-cell infiltration in the tumor site remain a major problem. To address this limitation, strategies
Shujie Zhou +4 more
doaj +3 more sources
For whom the T cells troll? Bispecific T-cell engagers in glioblastoma [PDF]
Journal for ImmunoTherapy of Cancer, 2021 Glioblastoma is the the most common primary brain tumor in adults. Onset of disease is followed by a uniformly lethal prognosis and dismal overall survival. While immunotherapies have revolutionized treatment in other difficult-to-treat cancers, these have failed to demonstrate significant clinical benefit in patients with glioblastoma.
Kirit Singh +5 more
openaire +3 more sources
Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy? [PDF]
Clinical and Experimental Immunology, 2023 Summary B and T cells collaborate to drive autoimmune disease (AID). Historically, B- and T-cell (B–T cell) co-interaction was targeted through different pathways such as alemtuzumab, abatacept, and dapirolizumab with variable impact on B-cell depletion (BCD), whereas the majority of patients with AID including rheumatoid arthritis ...
Kavina Shah +6 more
openaire +3 more sources
Generalizable design parameters for soluble T cell receptor-based T cell engagers [PDF]
Journal for ImmunoTherapy of Cancer, 2022 While most biological and cellular immunotherapies recognize extracellular targets, T cell receptor (TCR) therapeutics are unique in their ability to recognize the much larger pool of intracellular antigens found on virus-infected or cancerous cells.
Karen J Froning +3 more
openaire +3 more sources
Regulatory T cells hamper the efficacy of T-cell-engaging bispecific antibody therapy
Haematologica, 2023 T-cell-engaging bispecific antibodies (T-BsAb) have produced impressive clinical responses in patients with relapsed/refractory B-cell malignancies, although treatment failure remains a major clinical challenge. Growing evidence suggests that a complex interplay between immune cells and tumor cells is implicated in the mechanism of action and therefore,
Casey, M +7 more
openaire +6 more sources
Bispecific T‐cell engagers for cancer immunotherapy [PDF]
Immunology & Cell Biology, 2014 Bispecific T‐cell engagers (BiTEs) are a new class of immunotherapeutic molecules intended for the treatment of cancer. These molecules enhance the patient's immune response to tumors by retargeting T cells to tumor cells. BiTEs are constructed of two single‐chain variable fragments (scFv) connected in tandem by a flexible linker. One scFv binds to a T‐
Amelia M, Huehls +2 more
openaire +2 more sources
Engager T Cells: A New Class of Antigen-specific T Cells That Redirect Bystander T Cells [PDF]
Molecular Therapy, 2015 Adoptive immunotherapy with antigen-specific T cells has shown promise for the treatment of malignancies. However, infused T cells are unable to redirect resident T cells, limiting potential benefit. While the infusion of bispecific T-cell engagers can redirect resident T cells to tumors, these molecules have a short half-life, and do not self amplify.
Iwahori, Kota +7 more
openaire +2 more sources
Frontiers in Immunology, 2023 The application of immunotherapies such as chimeric antigen receptor (CAR) T therapy or bi-specific T cell engager (BiTE) therapy to manage myeloid malignancies has proven more challenging than for B-cell malignancies. This is attributed to a shortage of
Gianna M. Branella +30 more
doaj +1 more source
Designing Cancer Immunotherapies That Engage T Cells and NK Cells
Annual Review of Immunology, 2023 T cells and natural killer (NK) cells have complementary roles in tumor immunity, and dual T cell and NK cell attack thus offers opportunities to deepen the impact of immunotherapy. Recent work has also shown that NK cells play an important role in recruiting dendritic cells to tumors and thus enhance induction of CD8 T cell responses, while IL-2 ...
Oleksandr, Kyrysyuk +1 more
openaire +2 more sources
Frontiers in Immunology, 2023 T cell engagers, a category of T cell-retargeting immunotherapy, are rapidly transforming clinical cancer care. However, the lack of tumor-specific targets poses a significant roadblock for broad adaptation of this therapeutic modality in many ...
Even Walseng +7 more
doaj +1 more source